Mitochondria-targeted antioxidant peptides

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3124-3131

  Rocha, Milagros ^a   Hernandez Mijares, Antonio ^a,b   Garcia Malpartida, Katherinne ^a   Bañuls, Celia ^a,b   Bellod, Lorena ^a   Victor, Victor M ^a,b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antioxidant peptides; Mitochondria; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM ION; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CYTOCHROME C; EBSELEN; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROGEN PEROXIDE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOE2; MITOQ; MITOQ10; NUCLEIC ACID; PEPTIDE DERIVATIVE; PEROXYNITRITE; PHOSPHONIUM DERIVATIVE; PRODRUG; REACTIVE OXYGEN METABOLITE; SS 01 PEPTIDE; SS 02 PEPTIDE; SS 20 PEPTIDE; SS 31 PEPTIDE; SUPEROXIDE DISMUTASE; TAURINE; TOCOPHEROL; UBIQUINOL; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CELL PROTECTION; CLINICAL TRIAL; CYTOPATHOLOGY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; ENZYME RELEASE; GENE MUTATION; HEPATITIS; HUMAN; HYPOTENSION; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITOCHONDRION SWELLING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; STUNNED HEART MUSCLE;

ANIMALS; ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PEPTIDES; REACTIVE OXYGEN SPECIES;

EID: 78649897034     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292519     Document Type: Article

References (73)

1. Dhalla, NS, Temsah RM, Netticadan T. Role of oxidative stress in cardio-vascular diseases. J Hypertens 2000;18: 655-73.
2. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 2006; 13: 129-42.
3. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-28.
4. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 1998; 8: 267-71.
5. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1014-30.
6. Ballinger SW, Patterson C, Knight-Lozano CA, et al. Mitochondrial integrity and function in atherogenesis. Circulation 2002; 106: 544-9.
7. Dimmeler S, Zeiher AM. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerosic factors. Regul Pept 2000; 90: 19-25.
8. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26: 463-71.
9. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009; 16: 4654-67.
10. Rocha M, Esplugues JV, Hernandez-Mijares A, Victor VM. Mitochondrial-targeted antioxidants and oxidative stress: a proteomic prospective study. Curr Pharm Des 2009; 15: 3052-62.
11. Victor VM, Rocha M, Sola E, Bañuls C, Garcia-Malpartida K, Hernandez-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15: 2988-3002.
12. VM. Oxidative stress and cellular homeostasis. Curr Pharm Des 2009; 15: 2986-7.
13. Victor VM, Rocha M, De la Fuente M. N-acetylcysteine protects mice from lethal endotoxemia by regulating the redox state of immune cells. Free Radic Res 2003; 37: 919-29.
14. Victor VM, Rocha M, De la Fuente M. Immune cells: free radicals and antioxidants in sepsis. Int Immunopharmacol 2004; 4: 327-47.
15. Victor VM, Rocha M, Esplugues JV, De la Fuente M. Role of free radicals in sepsis: antioxidant therapy. Curr Pharm Des 2005; 11: 3141-58.
16. González R, Collado JA, Nell S, et al. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured Dgalactosamine-treated human hepatocytes. Free Radic Biol Med 2007; 43: 1439-52.
17. González R, Ferrín G, Hidalgo AB, et al. N-acetylcysteine, coenzyme Q10 and superoxide dismutase mimetic prevent mitochondrial cell dysfunction and cell death induced by d-galactosamine in primary culture of human hepatocytes. Chem Biol Interact 2009; 181(1): 95-106.
18. Kagan VE, Serbinova EA, Stoyanovsky DA, Khwaja S, Packer L. Assay of ubiquinones and ubiquinols as antioxidants. Methods Enzymol 1994; 234: 343-54.
19. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 2006; 1762: 256-65.
20. Víctor VM, Esplugues JV, Hernández-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets 2009; 9: 376-89.
21. Houstek J, Pickova A, Vojtiskova A, Mracek T, Pecina P, Jesina P. Mitochondrial diseases and genetic defects of ATP synthase. Biochim Biophys Acta 2006; 1757: 1400-5.
22. Victor VM, Nuñez C, D'Ocón P, Taylor CT, Esplugues JV, Moncada S. Regulation of oxygen distribution in tissues by endothelial nitric oxide. Circ Res 2009; 104: 1178-83.
23. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: 817-33.
24. Victor VM, Rocha M, Bañuls C, et al. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2009; 94: 3505-12.
25. Di Lisa F, Bernardi P. Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Cardiovasc Res 2005; 66: 222-32.
26. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-9.
27. Victor VM, Rocha M. Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des 2007; 13: 845-63.
28. Rocha M, Victor VM. Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med Sci Monit 2007; 13: 132-45.
29. Devary Y, Rosette C, DiDonato JA, Karin M. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261: 1442-5.
30. Schulze-Osthoff K, Beyaert R, Vandervoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J 1993; 12: 3095-104.
31. Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000; 41: 235-50.
32. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283: 1482-8.
33. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56.
34. Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondriatargeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003; 17: 1972-4.
35. Melov S, Coskun P, Patel M, et al. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci USA 1999; 96: 846-51.
36. Melov S, Doctrow SR, Schneider JA, et al. Lifespan extension and rescue of spongiform encephalopaty in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 2001; 21: 8348-53.
37. Schulz E, Anter E, Keaney JF. Oxidative stress, antioxidants, and endothelial function. Curr Med Chem 2004; 11: 1093-104.
38. V. Mitochondrial-targeted drug and DNA delivery. Crit Rev Ther Drug Carrier Syst 2003; 20: 1-62.
39. Anders MW, Robotham JL, Sheu SS. Mitochondria: new drug targets for oxidative stress-induced diseases. Expert Opin Drug Metab Toxicol 2006; 2: 71-9.
40. Ripcke J, Zarse K, Ristow M, Birringer M. Small-molecule targeting of the mitochondrial compartment with an endogenously cleaved reversible tag. ChemBioChem 2009; 10: 1689-96.
41. Roser KS, Brookes PS, Wojtovich AP, et al. Mitochondrial biotransformation of omega-(phenoxy)alkanoic acids, 3-(phenoxy) acrylic acids, and omega-(1-methyl-1H-imidazol-2-ylthio)alkanoic acids: a prodrug strategy for targeting cytoprotective antioxidants to mitochondria. Bioorg Med Chem 2010; 18: 1441-8.
42. Asin-Cayuela J, Manas AR, James AM, Smith RA, Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett 2004; 571: 9-16.
43. Smith RA, Porteous CM, Coulter CM, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999; 263: 709-716.
44. Brown SE, Ross MF, Sanjuan-Pla A, Manas AR, Smith RA, Murphy MP. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium-conjugated alphalipoyl derivative. Free Radic Biol Med 2007; 42: 1766-80.
45. Smith RA, Adlam VJ, Blaikie FH, et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci 2008; 1147: 105-11.
46. Filipovska A, Eccles MR, Smith RA, Murphy MP. Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEBS Lett 2004; 556: 180-6.
47. Ross MF, Kelso GF, Blaikie FH, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc.) 2005; 70: 222-30.
48. Koopman WJ, Verkaart S, Visch HJ, et al. Inhibition of complex I of the electron transport chain causes O2-mediated mitochondrial outgrowth. Am J Physiol Cell Physiol 2005; 288: C1440-50.
49. Esplugues JV, Rocha M, Nuñez C, et al. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrialtargeted antioxidants. Circ Res 2006; 99: 1067-75.
50. González-Rubio S, Hidalgo AB, Ferrín G, et al. Mitochondrialdriven ubiquinone enhances extracellular calcium-dependent nitric oxide production and reduces glycochenodeoxycholic acid-induced cell death in hepatocytes. Chem Res Toxicol 2009; 22: 1984-91.
51. Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 2003; 100: 5407-12.
52. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005; 19: 1088-95.
53. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
54. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitocondrial membrane inhibit mitocondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279: 34682-90.
55. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 2006; 8: 277-83.
56. Winterbourn CC, Parsons-Mair HN, Gebicki S, Gebicki JM, Davies MJ. Requirements for superoxide-dependent tyrosine hydroperoxide formation in peptides. Biochem J 2004; 381: 241-8.
57. Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther 2003; 304: 425-32.
58. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18188-93.
59. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 2003; 278: 31192-201.
60. Haidara K, Morel I, Abalea V, Gascon BM, Denizeau F. Mechanism of tert-butylhydroperoxide-induced apoptosis in rat hepatocytes: involvement of mitochondria and endoplasmic reticulum. Biochim Biophys Acta 2002; 1542: 173-85.
61. Piret JP, Arnould T, Fuks B, Chatelain P, Remacle J, Michiels C. Mitochondria permeability transition-dependent tert-butyl hydroperoxide-induced apoptosis in hepatoma HepG2 cells. Biochem Pharmacol 2004; 67: 611-20.
62. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-96.
63. Batandier C, Leverve X, Fontaine E. Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem 2004; 279: 17197-204.
64. Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coron Artery Dis 2001; 12: 363-9.
65. Wu D, Soong Y, Zhao GM, Szeto HH. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am J Physiol Heart Circ Physiol 2002; 283: 783-91.
66. Song W, Shin J, Lee J, et al. A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats. Coron Artery Dis 2005; 16: 407-10.
67. Thomas D, Zhao K, Stauffer C, et al. Mitochondrial targeting of islets with the cell permeant anti-oxidant peptide SS-31 reduces islet cell apoptosis and improves post-transplant function. J Am Soc Nephrol 2007; 18: 213-22.
68. Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol 2008; 295: F1545-53.
69. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal F. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxidants & Redox Signaling 2009; 11: 2095-104.
70. Szeto HH, Lovelace JL, Fridland G, et al. In vivo pharmacokinetics of selective mu-opioid peptide agonists. J Pharmacol Exp Ther 2001; 298: 57-61.
71. Cataldi A. Cell responses to oxidative stressors. Curr Pharm Des 2010; 16(12): 1387-95.
72. Rocha M, Esplugues JV, Hernandez-Mijares A, Victor VM. Mitochondrial-targeted antioxidants and oxidative stress: a proteomic prospective study. Curr Pharm Des 2009; 15(26): 3052-62.
73. Victor VM, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15(26): 2988-3002